![]() |
|
![]() |
|
ROTH Capital Partners Acts as Sole Placement Agent |
|
For more information please contact:
Investment Banking
Eric B. Cheng
Equity Capital Markets |
Transaction Information Seelos Therapeutics, Inc. intends to use the proceeds from the capital increase to finance research and development of clinical pipeline candidates, as well as for working capital and other general corporate purposes. ROTH Capital Partners acted as sole placement agent for the offering.
About Seelos Therapeutics, Inc.
About ROTH Capital Partners |
Date of Announcement: 2/7/19 The material, information and facts discussed in this announcement other than the information regarding ROTH Capital Partners, LLC ("ROTH") and its affiliates, are from sources believed to be reliable, but are in no way guaranteed to be complete or accurate. This announcement should not be used as a complete analysis of any companies, securities or topics discussed herein. Additional information is available upon request. This is not, however, an offer or solicitation of the securities discussed. Any opinions or estimates in this announcement are subject to change without notice. An investment in any security based on this announcement may involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Additionally, such investments may involve a high degree of risk and may not be suitable for all investors. No part of this announcement may be reproduced in any form without the express written permission of ROTH. Copyright 2019. |
|
|